Edge
StocktwitsEarnings

Official STOCKTWITS Representative

$TGTX Q2 '26 Earnings Results & Recap
• Reported GAAP EPS of $0.05 down -73.68% YoY
• Reported revenue of $240.34M up 70.27% YoY
• TG Therapeutics raised its full year 2026 total global revenue target to approximately $950 million and BRIUMVI U.S. net product revenue target to approximately $890 - $905 million for the company.Price since post
Advertisement|Remove ads.